Compare Equinix Inc (EQIX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs GeneDx Holdings Corp — how do they compare? Equinix Inc trades at $1,026.06 (market cap $99.77B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Equinix Inc is far larger — about 49.4× GeneDx Holdings Corp's market cap, and Equinix Inc pays a 2.04% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and GeneDx Holdings Corp for 19 Days on average.
| EQIX | WGS | |
|---|---|---|
Market Cap | $99.77B | $2.02B |
Volume | 480,425 | 734,640 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $167.51 |
52-Week Low | $726.09 | $34.51 |
Typical Hold Time | 110 Days | 19 Days |
Enterprise Value | $120.90B | $2.05B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,011.16, down 2.0% on the day amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $9.22B in 2025 and a net income margin of 15.63%, though valuation ratios like a P/E of 65.07 appear elevated. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 and Q4 2025 missing. Analyst sentiment remains bullish with a $1,250 consensus price target, supported by strong AI-driven data center demand highlighted in recent news.
The outlook for EQIX is positive due to robust AI infrastructure demand and a solid dividend, but risks include high capital expenditures and debt levels. Investors should weigh growth potential against valuation concerns and execution risks in a competitive sector.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
